ReviewTargeted oncology2021

Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09.

Akihito Tsuji et al.PubMed ↗Publisher ↗

No numbers read from the abstract.